Prediction of cytochrome P450-mediated hepatic drug clearance in neonates, infants and children: How accurate are available scaling methods?

Clinical Pharmacokinetics

Volumn 45, Issue 1, 2006, Pages 1-11

  Björkman, Sven ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; CYTOCHROME P450; DIAZEPAM; ENZYME; MIDAZOLAM;

ALLOMETRY; CALCULATION; CHILD; COMPUTER MODEL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG METABOLISM; DRUG RESEARCH; HEART SURGERY; HUMAN; IN VITRO STUDY; INFANT; NEWBORN; ONTOGENY; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; REVIEW;

AGING; ALFENTANIL; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INFANT; INFANT, NEWBORN; LIVER; METABOLIC CLEARANCE RATE; MIDAZOLAM; MODELS, BIOLOGICAL; PHARMACOKINETICS; PREDICTIVE VALUE OF TESTS;

EID: 31344444671     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645010-00001     Document Type: Review

References (66)

1. Yaffe S, editor. Rational therapeutics for infants and children: workshop summary. National Academy Press 2000 [online]. Available from URL: http://www.nap.edu/html/rational_therapeutics/ [Accessed 2004 Feb 13]
2. Baber N, Pritchard D. Dose estimation for children. Br J Clin Pharmacol 2003; 56: 489-93
3. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157-67
4. Strolin Benedetti M, Baltes EL. Drug metabolism and disposition in children. Fundam Clin Pharmacol 2003; 17: 281-99
5. Treluyer J-M, Jacqz-Aigrain E, Alvarez F, et al. Expression of CYP2D6 in developing human liver. Eur J Biochem 1991; 202: 583-8
6. Vieira I, Sonnier M, Cresteil T. Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Eur J Biochem 1996; 238: 476-83
7. Lacroix D, Sonnier M, Moncion A, et al. Expression of CYP3A in the human liver: evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997; 247: 625-34
8. Treluyer J-M, Gueret G, Cheron G, et al. Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility. Pharmacogenetics 1997; 7: 441-52
9. Sonnier M, Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 1998; 251: 893-8
10. Stevens JC, Hines RN, Gu C, et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 2003; 307: 573-82
11. Koukouritaki SB, Manro JR, Marsh SA, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004; 308: 365-74
12. de Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999; 37: 485-505
13. Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet 2002; 41: 959-98
14. Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clin Pharmacokinet 2002; 41: 1077-94
15. Johnson TN, Sabzghabaee A, Rostami-Hodjegan A, et al. Prediction of age related changes in midazolam clearance in children [abstract]. Br J Clin Pharmacol 2003; 55: 432-3
16. Johnson TN, Rostami-Hodjegan A, Tucker GT. A comparison of methods to predict drug clearance in neonates, infants and children [abstract]. Br J Clin Pharmacol 2004; 57: 677-8
17. Björkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 2005 Jun; 59 (6): 691-704
18. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003; 42: 59-98
19. Williams JA, Ring BJ, Cantrell VE, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002; 30: 883-91
20. Klees TM, Sheffels P, Dale O, et al. Metabolism of alfentanil by cytochrome P4503A (CYP3A) enzymes. Drug Metab Dispos 2005; 33: 303-11
21. Holford NHG. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30: 329-32
22. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469-79
23. McNamara PJ, Alcorn J. Protein binding predictions in infants. AAPS PharmSci 2002; 4 (1): E4
24. Haddad S, Restieri C, Krishnan K. Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans. J Toxicol Environ Health A 2001; 64: 453-64
25. Schuetz EG, Furuya KN, Schuetz JD. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 1995; 275: 1011-8
26. Greenblatt DJ, Abernethy DR, Locniscar A, et al. Effect of age, gender and obesity on midazolam kinetics. Anesthesiology 1984; 61: 27-35
27. Mandema JW, Tuk B, van Steveninck AL, et al. Pharmacokinetic- pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymida-zolam in healthy volunteers. Clin Pharmacol Ther 1992; 51: 715-28
28. Björkman S, Wada DR, Berling B-M, et al. Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model. J Pharm Sci 2001; 90: 1226-41
29. Mathews HML, Carson IW, Lyons SM, et al. A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. Br J Anaesth 1988; 61: 302-7
30. Jacqz-Aigrain E, Wood C, Robieux I. Pharmacokinetics of midazolam in critically ill neonates. Eur J Clin Pharmacol 1990; 39 (2): 191-2
31. Burtin P, Jacqz-Aigrain E, Girard P, et al. Population pharmacokinetics of midazolam in neonates. Clin Pharmacol Ther 1994; 56: 615-25
32. Reed MD, Rodarte A, Blumer JL, et al. The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. J Clin Pharmacol 2001; 41: 1359-69
33. de Wildt SN, de Hoog M, Vinks AA, et al. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. Crit Care Med 2003; 31: 1952-8
34. Schüttler J, Stoeckel H. Alfentanil (R 39209) ein neues kurzwirkendes Opioid. Pharmakokinetik und erste klinische Erfahrungen. Anaesthesist 1982; 31: 10-4
35. Bovill JG, Sebel PS, Blackburn CL, et al. The pharmacokinetics of alfentanil (R39209): a new opioid analgesic. Anesthesiology 1982; 57: 439-43
36. Camu F, Gepts E, Rucquoi M, et al. Pharmacokinetics of alfentanil in man. Anesth Analg 1982; 61: 657-61
37. Fragen RJ, Booij LHDJ, Braak GJJ, et al. Pharmacokinetics of the infusion of alfentanil in man. Br J Anaesth 1983; 55: 1077-81
38. Helmers H, van Peer A, Woestenborghs R, et al. Alfentanil kinetics in the elderly. Clin Pharmacol Ther 1984; 36: 239-43
39. Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age: a simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther 1987; 240: 159-66
40. van Beem H, van Peer A, Gasparini R, et al. Pharmacokinetics of alfentanil during and after a fixed rate infusion. Br J Anaesth 1989; 62: 610-5
41. Lemmens HJM, Burm AGL, Hennis PJ, et al. Influence of age on the pharmacokinetics of alfentanil: gender dependence. Clin Pharmacokinet 1990; 19: 416-22
42. Goresky GV, Koren G, Sabourin MA, et al. The pharmacokinetics of alfentanil in children. Anesthesiology 1987; 67: 654-9
43. Wiest DB, Ohning BL, Garner SS. The disposition of alfentanil in neonates with respiratory distress. Pharmacotherapy 1991; 11: 308-11
44. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50: 222-39
45. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet 2002; 41: 329-42
46. Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 2002; 72: 474-89
47. Wandel C, Kim R, Wood M, et al. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 2002; 96: 913-20
48. Rubio A, Cox C. Sex, age and alfentanil pharmacokinetics [letter]. Clin Pharmacokinet 1991; 21: 81-2
49. Power BM, Forbes AM, van Heerden PV, et al. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998; 34: 25-56
50. Anderson BJ, McKee AD, Holford NHG. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin Pharmacokinet 1997; 33: 313-27
51. Fahey JT. Developmental aspects of hepatic blood flow. In: Suchy FJ, editor. Liver disease in children. St Louis (MO): Mosby-Year Book Inc, 1994: 31-8
52. Kamdem LK, Meineke I, Koch I, et al. Limited contribution of CYP3A5 to the hepatic 6β-hydroxylation of testosterone. Naunyn Schmiedeberg's Arch Pharmacol 2004; 370: 71-7
53. Ono S, Hatanaka T, Miyazawa S, et al. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 1996; 26: 1155-66
54. Yang TJ, Shou M, Korzekwa KR, et al. Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam. Biochem Pharmacol 1998; 55: 889-96
55. Yee GC, Lennon TP, Gmur DJ, et al. Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther 1986; 40: 438-43
56. Yee GC, McGuire TR, Gmur DJ, et al. Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation. Transplantation 1988; 46: 399-402
57. Ginsberg G, Hattis D, Sonawane B. Incorporating pharmacokinetic differences between children and adults in assessing children's risk to environmental toxicants. Toxicol Appl Pharmacol 2004; 198: 164-83
58. Kharasch ED, Russell M, Garton K, et al. Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Anesthesiology 1997; 87: 26-35
59. Kharasch ED, Russell M, Mautz D, et al. The role of cytochrome P450 3A4 in alfentanil clearance: implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 1997; 87: 36-50
60. Phimmasone S, Kharasch ED. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. Clin Pharmacol Ther 2001; 70: 505-17
61. Kharasch ED, Hoffer C, Walker A, et al. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. Clin Pharmacol Ther 2003; 73: 199-208
62. Kharasch ED, Walker A, Hoffer C, et al. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther 2004; 76: 452-66
63. Meuldermans WEG, Hurkmans RMA, Heykants JJP. Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood. Arch Int Pharmacodyn 1982; 257: 4-19
64. Chauvin M, Lebrault C, Levron JC, et al. Pharmacokinetics of alfentanil in chronic renal failure. Anesth Analg 1987; 66: 53-6
65. Hug CC, Burm AGL, de Lange S. Alfentanil pharmacokinetics in cardiac surgical patients. Anesth Analg 1994; 78: 231-9
66. Maitre PO, Vozeh S, Heykants J, et al. Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients. Anesthesiology 1987; 66: 3-12